A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

Carcinoma Clinical Trial

Official title:

Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00477425
• Other study ID #: AVF4223g
• Status: Withdrawn
• Phase: N/A
• First received: May 21, 2007
• Last updated: May 11, 2017
• Start date: June 2007
• Est. completion date: June 2007

Study information

• Verified date: May 2017
• Source: Genentech, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2007
• Est. primary completion date: June 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Signed Informed Consent Form

• Enrollment in one of a list of certain randomized, controlled bevacizumab trials

Exclusion Criteria:

• Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)

• Congenital long QT syndrome

• Family history of long QT syndrome

• Clinically significant bradycardia (defined as < 50 beats/minute)

Related Conditions & MeSH terms

• Carcinoma

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Genentech, Inc.